FIRST OF THREE STEPS TOWARD BRINGING NOVEL RADIOISOTOPE PRODUCTION PLATFORM ONLINE
Novel gel embolic designed to give physicians greater control and consistency during embolization.
BioUtah, alongside state and local partners, showcased Utah’s booming $22.6B+ life sciences sector at the BIO International Convention, June 22-25, at the San Diego Convention Center. Through the Utah Pavilion Exhibit, the delegation boosted the state’s global profile as a premier bioscience hub. A number of meetings with entrepreneurs and companies interested in Utah’s bio […]
SINTX’s advanced ceramic manufacturing platform supports customers across multiple industries requiring high-performance materials.
Aligns With Growing Focus on Early Identification and Management of Preterm Birth Risk
The whole-genome sequencing assay is now available for breast, colorectal, and renal cancers following new clinical study results.
AI-powered voice analysis is now available to clinicians directly inside Zoom, transforming routine telehealth conversations into early signals for behavioral and cognitive health
The Utah Pavilion will serve as a gathering place to help convention attendees discover the state’s vibrant life sciences industry and the sector’s unique culture of collaboration that drives innovation.
The designation follows encouraging Phase 2 clinical trial results.
Proceeds from transaction to support advancement of Denali’s broad TransportVehicle™-enabled clinical portfolio for lysosomal storage disorders and neurodegenerative diseases.
Visit has included tour of Utah headquarters and automated manufacturing facilities ahead of planned technology transfer.
First biodistribution study of the Company’s complete cancer targeting nanoparticle avoided many healthy organs.
The study, published in the Journal of Arthroplasty, highlighted that the Company’s NeuroCuple® Nanotechnology Device achieved statistically significant reduction in opioid use.
Build It Live at the HITLAB World Cup.
The DSMB review was conducted as part of the pre-planned clinical safety oversight process agreed upon with the U.S. FDA.
New 75,000-square-foot facility to open in October 2026 near Salt Lake City International Airport, extending company’s national reach for medical device manufacturers
The company’s comprehensive viral target atlas is designed to move development from reactive crisis response toward proactive, pre-identified genomic vulnerability mapping
nView medical announced that its nView s1 system has surpassed 1,000 surgeries, marking an important milestone in the clinical use of the company’s intraoperative 3D imaging and navigation technology.
University of Utah Launchpad Seed Fund award to support translational validation of NanoKar’s ITAM optimization platform, including CAR-T persistence and activity in solid tumor models.
Expanded collaboration adds manufacturing capacity, strengthens redundancy, and supports later-stage development planning for Ratio’s lead FAP-targeted radiotherapeutic candidate.
New PATHOMIQ AI integration helps clinicians tailor active surveillance with greater confidence
Joint development strategy has been developed to address international deployment requirements if current outbreak continues or expands globally
Mosman to lead NanoKar’s next phase of translational validation, partner readiness, and strategic collaboration for its ITAM optimization platform
Recognition places Lumea among elite global winners including Medtronic and Thermo Fisher Scientific in one of digital health’s most competitive annual programs
Recent pathogens illustrate need for improved situational awareness capabilities, such as those provided by the Co-Dx PCR point-of-care platform
Funds will fuel sales team expansion and broader market access, advancing the company’s leadership in Implantable Tibial Neuromodulation (ITNM) for the treatment of urgency urinary incontinence (UUI)
351-patient trial completion marks a key milestone for the Celeste® program; topline data to be presented May 26 in Phoenix
FDA stated that the “proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway” for CNM-Au8 based on neurofilament light (NfL) biomarker data
VOXZOGO is the only approved treatment for children with achondroplasia starting at birth, with over 10 years of clinical research demonstrating the long-term benefit on complications associated with achondroplasia
Two ARUP Medical Directors Receive Career Achievement Awards
As gaps in early detection persist, a 45-second voice analysis offers a new way to identify signals of stress, anxiety, and depression during Mental Health Awareness Month
What to Know About the Reauthorized SBIR/STTR Grant Programs
